Categories
Change Password!
Reset Password!
Six-month omalizumab therapy markedly improves disease control, quality of life, and prevents wheal formation in patients with delayed pressure urticaria.
A retrospective observational study has revealed that omalizumab, a monoclonal antibody commonly used for chronic urticaria, may offer remarkable benefits for patients with delayed pressure urticaria (DpU), a difficult-to-manage subtype of inducible urticaria.
DpU is characterized by painful, red swellings that develop several hours after pressure is applied to the skin, often hampering daily activities and quality of life. While omalizumab is already an established treatment for chronic spontaneous urticaria (CSU), evidence for its role in managing DpU has been limited. Hence, this study, which reviewed medical records of 78 patients with CSU or DpU who were treated with omalizumab, assessed treatment outcomes at 6 months. Researchers evaluated disease control using the Urticaria Control Test (UCT), the Dermatology Life Quality Index (DLQI), and a pressure provocation test designed to confirm DpU activity.
Results showed a remarkable increase in UCT scores across all patient groups, including those with CSU alone and those with both CSU and DpU. Similarly, DLQI scores improved significantly, highlighting a better quality of life. Importantly, when patients underwent a pressure provocation test after 6 months of treatment, none developed urticarial wheals at the pressure site within 6 hours, suggesting a strong therapeutic response. Hence, omalizumab appears to offer a valuable treatment option for DpU sufferers, particularly those who have struggled with limited alternatives.
Allergy and Asthma Proceedings
Delayed pressure urticaria successfully treated with omalizumab: A tertiary-level health-care center experience
Mehmet Erdem Cakmak et al.
Comments (0)